WO2006066001A2 - Immobilized degradable cationic polymer for transfecting eukaryotic cells - Google Patents
Immobilized degradable cationic polymer for transfecting eukaryotic cells Download PDFInfo
- Publication number
- WO2006066001A2 WO2006066001A2 PCT/US2005/045429 US2005045429W WO2006066001A2 WO 2006066001 A2 WO2006066001 A2 WO 2006066001A2 US 2005045429 W US2005045429 W US 2005045429W WO 2006066001 A2 WO2006066001 A2 WO 2006066001A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- transfection
- cell
- formula
- degradable
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Definitions
- Embodiments of the invention relate to devices and methods for cell transfection.
- embodiments of the invention are directed to a cell transfection formula and to a cell culture device that has been treated with the transfection formula.
- the treated cell culture device can be stored at room temperature and provides a transfection method that is simple and quick.
- Gene transfection methods can be used to introduce nucleic acids into cells and are useful in studying gene regulation and function. High throughput assays that can be used to screen large sets of DNAs to identify those encoding products with properties of interest which are particularly useful. Gene transfection is the delivery and introduction of biologically functional nucleic acids into a cell, particularly a eukaryotic cell, in such a way that the nucleic acid retains its function within the cell. Gene transfection is widely applied in studies related to gene regulation, gene function, molecular therapy, signal transduction, drug screening, and gene therapy studies. As the cloning and cataloging of genes from higher organisms continues, researchers seek to discover the function of the genes and to identify gene products with desired properties. This growing collection of gene sequences requires the development of systematic and high-throughput approaches to characterizing gene products and analyzing gene function, as well as other areas of research in cell and molecular biology.
- Non-viral carriers are simpler and more cost effective in comparison to preparation of viral carriers, making synthetic gene carriers desirable as transfection reagents, particularly for in vitro studies.
- Most non-viral vectors mimic important features of viral cell entry in order to overcome cellular barriers, which are meant to prevent infiltration by foreign genetic material.
- Non-viral gene vectors based on a gene carrier backbone, can be classified as a) lipoplexes, b) polyplexes, and c) lipopolyplexes.
- Lipoplexes are assemblies of nucleic acids with a lipidic component, which is usually cationic. Gene transfer by lipoplexes is called lipofection.
- Polyplexes are complexes of nucleic acids with cationic polymer.
- Lipopolyplexes comprise both a lipid and a polymer component. Often such DNA complexes are further modified to contain a cell targeting or an intracellular targeting moiety and/or a membrane-destabilizing component, for example, a viral protein or peptide or a membrane-disruptive synthetic peptide. Recently, bacteria and phages have also been described as shuttles for the transfer of nucleic acids into cells.
- non-viral transfection reagents are synthetic cationic molecules and have been reported to "coat" the nucleic acid by interaction of the cationic sites on the cation and anionic sites on the nucleic acid.
- the positively-charged DNA-cationic molecule complex interacts with the negatively charged cell membrane to facilitate the passage of the DNA through the cell membrane by non-specific endocytosis. (Schofield, Brit. Microencapsulated. Bull, 51(1):56-71 (1995)).
- the cells are seeded on cell culture devices 16 to 24 hours before transfection.
- the transfection reagent (such as a cationic polymer carrier) and DNA are usually prepared in separate tubes, and each respective solution is diluted in medium (containing no fetal bovine serum or antibiotics). The solutions are then mixed by carefully and slowing adding one solution to the other while continuously vortexing the mixture. The mixture is incubated at room temperature for 15-45 minutes to allow complex formation between the transfection reagent and the DNA and to remove residues of serum and antibiotics. Prior to transfection, the cell culture medium is removed and the cells are washed with buffer. The solution containing the DNA-transfection reagent complexes is added to the cells, and the cells are incubated for about 3-4 hours. The medium containing the transfection reagent is then be replaced with fresh medium. The cells are finally analyzed at one or more specific time point(s). This is obviously a time consuming procedure, particularly when the number of samples to be transfected is very large.
- Results derived from multi- step procedures are often influenced by human or mechanical error or other variations at each step, hi addition, refreshing the cell culture medium following transfection disturbs the cells and may cause them to detach from the surface on which they are cultured, thus leading to variation and unpredictability in the final results. Due to all the factors noted, conventional transfection methods require a highly skilled individual to perform the transfection experiment or assay.
- transfection is a lengthy and technically difficult procedure. Generally, three steps are required: 1) cells are seeded in a cell culture plate or dish and incubated until sufficient confluence is achieved; 2) transfection reagent / nucleic acid complexes are prepared; and 3) nucleic acids of interest are added along with the transfection reagent and further incubation is carried out. Two incubation periods are needed and typically it takes more than two days to complete all the steps. In contrast, embodiments of the present invention provide a simple procedure that involves only a single incubation step. A cell culture device, which has previously been coated with a transfection reagent, allows transfection by adding the nucleic acid of interest and the cell culture in succession.
- the transfected cells may then be cultured in the same device.
- the cells may be transfected and cultured in the cell culture device without the need for further manipulation of the cells immediately after the transfection step.
- Transfection efficiency is comparable to regular transfection, but the time required for the operation is reduced by more than one day.
- Embodiments of the invention include a transfectable cell culture device which greatly reduces the labor of transfection assays, and enables transfection with any nucleic acid of interest in an easy method with low cytotoxicity.
- the transfectable cell culture device of the invention is stable for long term storage at room temperature.
- Embodiments of the invention are directed to a device which includes a solid support coated with a transfection reagent mixture.
- the transfection reagent in the coating is not complexed with a biomolecule, such as a nucleic acid.
- the solid support is polystyrene resin, epoxy resin or glass.
- the coating is on the surface of the solid support.
- the coating amount of the transfection reagent is from about 0.1 to about 100 ⁇ g/cm2.
- the transfection agent is a polymer. More preferably, the polymer is a cationic polymer.
- the transfection agent comprises a degradable cationic polymer.
- the degradable cationic polymer is made by linking cationic compounds or oligomers with degradable linkers.
- the transfection agent may comprise both a degradable cationic polymer and a non-degradable cationic polymer.
- the ratio of the non-degradable cationic polymer to the degradable cationic polymer is 1:0.5 to 1:20 (non-degradable : degradable) by weight.
- the transfection reagent includes a plurality of cationic molecules and at least one degradable linker molecule connecting said cationic molecules in a branched arrangement, wherein said cationic molecules are selected from : (i) a cationic compound of formula (A) or (B) or a combination thereof:
- R 1 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, another Formula A, or
- R 2 is a straight chain alkylene group of the formula: -(CH 2 ) a - wherein a is an integer number from 2 to 10;
- R 3 is a straight or branched chain alkylene group of the formula: -(CbH 2 b)- wherein b is an integer number from 2 to 10;
- R 4 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, another Formula A, or Formula B;
- R 5 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, another Formula A, or Formula B;
- R 6 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, Formula A, or another Formula B;
- R 7 is a straight or branched chain alkylene group of the formula: -(C c H 2c )- in which c is an integer number from 2 to 10;
- R 8 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, Formula A, or another Formula B;
- the cationic compound or oligomer is poly(L-lysine) (PLL), polyethyleneimine (PEI), polypropyleneimine (PPI), pentaethyleneamine, N,N'- bis(2-arninoethyl)- 1 ,3 -propanediamine, N 5 N' -bis(2-aminopropyl)-ethylenediamine, spermine, spermidine, N-(2-aminoethyl)- 1,3 -propanediamine, N-(3-aminopropyl)-l,3- propanediamine, tri(2-aminoethyl)amine, l,4-bis(3-aminopropyl)piperazine, N-(2- aminoethyl)p
- the linker molecule is di- and multi-acrylates, di- and multi-acrylamides, di- and multi-isothiocyanates, di- and multi-isocyanates, di- and multi- epoxides, di- and multi-aldehydes, di-and multi-acyl chlorides, di- and multi-sulfonyl chlorides, di- and multi-halides, di- and multi-anhydrides, di- and multi-maleimides, di- and multi-N-hydroxysuccinimide esters, di- and multi-carboxylic acids, or di-and multi-a- haloacetyl groups.
- the linker molecule is 1,3-butanediol diacrylate, 1,4- butanediol diacrylate, 1,6-hexanediol diacrylate, 2,4-pentanediol diacrylate, 2-methyl-2,4- pentanediol diacrylate, 2,5-dimethyl-2,5-hexanediol diacrylate, poly(ethylene glycol) diacrylate, trimethylolpropane triacrylate, pentaerythritol tetraacrylate, di(trimethylolpropane) tetraacrylate, dipentaerythritol pentaacrylate, or a polyester with at least three acrylate or acrylamide side groups.
- the molecular weight of the polymer is from 500 da to
- the molecular weight of the polymer is from 2000 da to 200,000 da.
- the molecular weight of the cationic compound or oligomer is from 50 da to 10,000 da. In preferred embodiments, the molecular weight of the linker molecule is from 100 da to 40,000 da.
- the solid support is a dish bottom, a multi-well plate, or a continuous surface.
- the transfection agent is covalently associated with a nucleic acid. In other preferred embodiments, the transfection agent is non-covalently associated with a nucleic acid.
- the device can be stored at room temperature for at least 5 months without significant loss of transfection activity.
- Embodiments of the invention are directed to a method of cell transfection which includes the steps of adding a solution including a nucleic acid to be transfected to a device which includes a solid support coated with a transfection reagent mixture, adding eukaryotic cells to the solution; and incubating the cells and the nucleic acid solution to allow cell transfection.
- the incubation is for 5 min. to 3 hours. More preferably, the incubation is for 10 min. to 90 min.
- the nucleic acid is DNA, PxNA, DNA/RNA hybrid or chemically- modified nucleic acid. More preferably, the DNA is circular (plasmid), linear, fragment or single strand oligonucleotide (ODN). More preferably, the RNA is single strand (ribozyme) or double strand (siPvNA).
- the cell is a mammalian cell. hi some preferred embodiments, at least some of the cells undergo cell division, hi some preferred embodiments, the cell is a transformed or primary cell. In some preferred embodiments, the cell is a somatic or stem cell. In some preferred embodiments, the cell is a plant cell. Further aspects, features and advantages of this invention will become apparent from the detailed description of the preferred embodiments which follow.
- Figure 1 shows the cell shape of transfected 293 cells.
- the transfection agent treatments were linear polyethyleneimine (L-PEI) based polymer, lipid based polymer, degradable cationic polymer, and no treatment (intact 293 cells).
- Figure 2 shows percentage of EGFP- positive cells.
- FIG. 3 shows cell condition after transfection.
- Figure 4 shows the stability of a transfectable cell culture device in a mylar bag with O 2 absorber.
- Figure 5 shows the stability of a transfectable cell culture device in a mylar bag with CO 2 absorber.
- Figure 6 shows the stability of a transfectable cell culture device in a mylar bag with O 2 and CO 2 absorber.
- Figure 7 shows the stability of a transferable cell culture device in a mylar bag.
- Embodiments of the invention are directed to a transfection device and method which is simple, convenient, and efficient compared to conventional transfection assays.
- a transfection device is made according to methods described herein by affixing a transfection reagent on the solid surface of a cell culture device. By using this device, researchers need only add a nucleic acid or other biomolecule to be transfected and cells to the surface of the cell culture device. There is no need to pre-mix the DNA or biomolecule with a transfection reagent. This removes a key timing-consuming step, which is required by conventional transfection procedures. Only approximately 40 minutes is required to complete the entire transfection process for 10 samples, compared to 2 to 5 hours or more required by current methods. This is particularly advantageous for high throughput transfection assays, in which hundreds of samples are tested at a time.
- transfection device that is very easy to store, and it provides a simple method for biomolecule delivery or gene transfection in which no biomaterial/transfection reagent mixing step is required.
- the transfection procedure described herein can be finished in a short period of time, for instance approximately 5 min. to 3 hours, and it provides a high throughput method for transfection or drug delivery in which large numbers of samples may be transfected at a time.
- transfection reagents are simply coated onto the surface of a cell culture device, which can be easily commercialized and mass-produced.
- An incubation period for a predetermined time allows the biomolecule and the transfection reagent(s) to form a complex for uptake by cells in the next step.
- Cells are then seeded on the surface of the cell culture device and incubated, without the necessity of changing the medium, and the cells are analyzed. Changing medium during the transfection procedure is unnecessary.
- the composition containing the transfection agent can be affixed to any suitable surface.
- the surface can be glass, plastics (such as polytetrafluoroethylene, polyvinylidenedifluoride, polystyrene, polycarbonate, polypropylene), silicon, metal (such as gold), membranes (such as nitrocellulose, methylcellulose, PTFE or cellulose), paper, biomaterials (such as protein, gelatin, agar), tissues (such as skin, endothelial tissue, bone, cartilage), or minerals (such as hydroxylapatite, graphite).
- the surfaces may be slides (glass or poly-L-lysine coated slides) or wells of a multi-well plate.
- the transfection reagent is fixed on the surface and dried, and then a nucleic acid of interest or a nucleic acid to be introduced into cells is introduced.
- a nucleic acid of interest or a nucleic acid to be introduced into cells is introduced.
- the nucleic acid is spotted onto the glass slide in a microarray. The slide is incubated at room temperature for 30 minutes to form nucleic acid/transfection reagent complexes on the surface of the transfection device.
- the nucleic acid/transfection reagent complexes create a medium for use in high throughput microarrays, which can be used to study hundreds to thousands of nucleic acids, or other biomolecules at the same time, hi an alternative embodiment, the transfection reagents can be affixed on the surface of the transfection device in discrete, defined regions to form a microarray of transfection reagents.
- biomolecules such as nucleic acids, which are to be introduced into cells, are spread on the surface of the transfection device and incubated with the transfection reagent microarray. This method can be used in screening transfection reagents or other delivery reagents from thousands of compounds. The results of such a screening method can be examined through computer analysis.
- one or more wells of a multi-well plate may be coated with one or more transfection reagent(s).
- Plates commonly used in transfection are 96-well and 384-well plates.
- the transfection reagent can be evenly applied to the bottom of each well in the multi-well plate.
- the transfection reagent is applied to the bottom of plate in the range of about 0.1 to about 100 ⁇ g/cm 2 .
- the coating amount of the transfection reagent may be varied depending on the type of well plate to be used.
- the coating concentration of the transfection reagent is preferably from about 0.5 to about 50 ⁇ g/cm 2 , and more preferably from about 1 to 20 ⁇ g/cm 2 .
- the coating concentration of the transfection reagent is preferably from about 0.5 to about 50 ⁇ g/cm 2 , and more preferably from about 1 to 30 ⁇ g/cm 2 .
- a 10-cm cell culture dish is coated with a transfection reagent.
- the transfection reagent can be evenly applied to the bottom of dish.
- the transfection reagent may be applied to the bottom of dish in the range of about 0.1 to about 100 ⁇ g/cm 2 , more preferably about 0.2 to about 20 ⁇ g/cm 2 .
- the transfection device is stored in a material suitable for packaging which may be plastic (e.g., cellophane), an elastomeric material, thin metal, Mylar®, or other polyester film material.
- the storage may be with or without oxygen and/or carbon dioxide absorbers.
- the transfection plates prepared as described herein may be stored for at least 5 months at room temperature with retention of significant cell- transfecting activity.
- the transfection reagent is preferably a cationic compound which can introduce biomolecules, such as nucleic acids into cells.
- Preferred embodiments use cationic oligomers, such as low molecular weight polyethyleneimine (PEI).
- the transfection agent is a degradable cationic polymer.
- the transfection agent includes a cell-targeting or an intracellular-targeting moiety and/or a membrane- destabilizing component, as well as delivery enhancers. In general, delivery enhancers fall into two categories. These are viral carrier systems and non- viral carrier systems. As human viruses have evolved ways to overcome the barriers to transport into the nucleus discussed above, viruses or viral components are useful in transport of nucleic acid into cells.
- the degradable polymers may be conjugated to or associated with a viral or non-viral protein to enhance transfection efficiency.
- a viral or non-viral protein for example, vesicular stomatitis virus G protein (VSVG) and other peptides or proteins which are known to those of skill in the art may be added to the polymers in order to improve transfection efficiency.
- VSVG vesicular stomatitis virus G protein
- other peptides or proteins which are known to those of skill in the art may be added to the polymers in order to improve transfection efficiency.
- HA-peptide hemagglutinin peptide
- This viral peptide facilitates transfer of biomolecules into cells by endosome disruption. At the acidic pH of the endosome, this protein causes release of the biomolecule and carrier into the cytosol.
- Non- viral delivery enhancers may be either polymer-based or lipid-based. They are generally polycations which act to balance the negative charge of the nucleic acid. Polycationic polymers have shown significant promise as non- viral gene delivery enhancers due in part to their ability to condense DNA plasmids of unlimited size and to safety concerns with viral vectors. Examples include peptides with regions rich in basic amino acids such as oligo-lysine, oligo-arginine or a combination thereof and polyethylenimine (PEI). These polycationic polymers facilitate transport by condensation of DNA. Branched chain versions of polycations such as PEI and Starburst dendrimers can mediate both DNA condensation and endosome release (Boussif, et al.
- PEI polyethylenimine
- PEI is a highly branched polymer with terminal amines that are ionizable at pH 6.9 and internal amines that are ionizable at pH 3.9 and because of this organization, can generate a change in vesicle pH that leads to vesicle swelling and eventually, release from endosome entrapment.
- Another means to enhance delivery is to design a ligand on the transfection reagent.
- the ligand must have a receptor on the cell that has been targeted. Biomolecule delivery into the cell is then initiated by receptor recognition. When the ligand binds to its specific cell receptor, endocytosis is stimulated.
- Examples of ligands which have been used with various cell types to enhance biomolecule transport are galactose, transferrin, the glycoprotein asialoorosomucoid, adenovirus fiber, malaria circumsporozite protein, epidermal growth factor, human papilloma virus capsid, fibroblast growth factor and folic acid.
- the bound ligand is internalized through a process termed potocytosis, where the receptor binds the ligand, the surrounding membrane closes off from the cell surface, and the internalized material then passes through the vesicular membrane into the cytoplasm (Gottschalk, et al. (1994) Gene Ther 1:185-191).
- Various agents have been used for endosome disruption. Besides the HA-protein described above, defective-virus particles have also been used as endosomolytic agents (Gotten, et al. (My 1992) Proc. Natl. Acad. Sci. USA vol. 89: pages 6094-6098).
- Non- viral agents are either amphiphillic or lipid-based.
- biomolecules such as DNA into the cytoplasm of the cell can be enhanced by agents that either mediate endosome disruption, decrease degradation, or bypass this process all together.
- Chloroquine which raises the endosomal pH, has been used to decrease the degradation of endocytosed material by inhibiting lysosomal hydrolytic enzymes (Wagner, et al. (1990) Proc Natl Acad Sci USA vol. 87: 3410-3414).
- Branched chain polycations such as PEI and starburst dendrimers also promote endosome release as discussed above.
- toxins such as Diptheria toxin and Pseudomonas exotoxin have been utilized as components of chimeric proteins that can be incorporated into a gene/gene carrier complex (Uherek, et al.(1998) J Biol. Chem. vol. 273: 8835-8841). These components promote shuttling of the nucleic acid through the endosomal membrane and back through the endoplasmic reticulum.
- nucleic acid Once in the cytoplasm, the nucleic acid must find its way to the nucleus. Localization to the nucleus may be enhanced by inclusion of a nuclear localization signal on the nucleic acid-carrier.
- a specific amino acid sequence that functions as a nuclear- localization signal (NLS) is used.
- the NLS on a cargo-carrier complex interacts with a specific nuclear transport receptor protein located in the cytosol. Once the cargo-carrier complex is assembled, the receptor protein in the complex is thought to make multiple contacts with nucleoporins, thereby transporting the complex through a nuclear pore. After a cargo-carrier complex reaches its destination, it dissociates, freeing the cargo and other components.
- Biodegradable cationic polymers typically exhibit low cytotoxicity, but also low transfection efficiency due to rapid degradation, making them less competitive against other carriers for gene transfer and other applications. These degradable cationic polymers improve transfection efficiency by linking low molecular weight cationic compounds or oligomers together with degradable linkers.
- the linker molecules may contain biologically, physically or chemically cleavable bonds, such as hydrolysable bonds, reducible bonds, a peptide sequence with enzyme specific cleavage sites, pH sensitive, or sonic sensitive bonds.
- the degradation of these polymers may be achieved by methods including, but not limited to hydrolysis, enzyme digestion, and physical degradation methods, such as optical cleavage (photolysis).
- One of the advantages of the degradable cationic polymers described herein is that degradation of the polymers is controllable in terms of rate and site of polymer degradation, based on the type and structures of the linkers.
- the transfection reagent includes a plurality of cationic molecules and at least one degradable linker molecule connecting said cationic molecules in a branched arrangement.
- Cationic oligomers such as low molecular weight polyethyleneimine (PEI), low molecular weight poly(L-lysine) (PLL), low molecular weight chitosan, and low molecular weight PAMAM dendrimers, can be used to make the polymers described herein. Furthermore, any molecule containing amines with more than three reactive sites can be used.
- PEI low molecular weight polyethyleneimine
- PLL low molecular weight poly(L-lysine)
- PAMAM dendrimers low molecular weight PAMAM dendrimers
- Cationic oligomers maybe selected from, but are not limited to:
- Formula B Formula A wherein R 1 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, another Formula A, or Formula B; R 2 is a straight chain alkylene group of the formula: -(CH 2 ) a - wherein a is an integer number from 2 to 10; R 3 is a straight chain alkylene group of the formula: -(Q,H 2b )- wherein b is an integer number from 2 to 10;
- R 4 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, another Formula A, or Formula B;
- R 5 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, another Formula A, or Formula B;
- R 6 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, Formula A, or another Formula B;
- R 7 a straight or branched chain alkylene group of the formula: -(C C H 2C )- in which c is an integer number from 2 to 10;
- R 8 is a hydrogen atom, an alkyl of 2 to 10 carbon atoms, Formula A, or another Formula B;
- cationic molecules examples include, but are not limited to, the cationic molecules shown in Table 1.
- Table 1 Structures of cationic compounds and oligomers according to preferred embodiments of the invention
- Cationic polymers used herein may include primary or secondary amino groups, which can be conjugated with active ligands, such as sugars, peptides, proteins, and other molecules.
- lactobionic acid is conjugated to the cationic polymers.
- the galactosyl unit provides a useful targeting molecule towards hepatocyte cells due to the presence of galactose receptors on the surface of the cells.
- lactose is conjugated to the degradable cationic polymers in order to introduce galactosyl units onto the polymer.
- Degradable linking molecules include, but are not limited to, di- and multi- acrylates, di- and multi-methacrylates, di- and multi-acrylaniides, di- and multi- isothiocyanates, di- and multi-isocyanates, di- and multi-epoxides, di- and multi-aldehydes, di- and multi-acyl chlorides, di- and multi-sulfonyl chlorides, di- and multi-halides, di- and multi-anhydrides, di- and multi-malemides, di- and multi-carboxylic acids, di- and multi- ⁇ - haloacetyl groups, and di- and multi-N-hydroxysuccinimide esters, which contain at least one biodegradable spacer.
- the following formula describes a linker which may be used according to preferred embodiments:
- A(Z) d wherein A is a spacer molecule having at least one degradable bond, Z is a reactive residue which reacts with amino group, and d is an integer equal to or more than two and wherein A and Z are bound covalently.
- Reactive residues of the linker molecules have been illustrated in Table 2, however these examples are not limiting to the scope of the invention.
- Reactive residues may be selected from, but are not limited to, acryloyl, maleimide, halide, carboxyl acylhalide, isocyanate, isothiocyanate, epoxide, aldehyde, sulfonyl chloride, and N-hydroxysuccinimide ester groups or combinations thereof.
- Table 2 Structures of biodegradable linker molecules used in preferred embodiments of the invention
- the degradation rates of the polymers can be controlled by changing the polymer composition, feed ratio, and the molecular weight of the polymers. For example, when linkers with bulkier alkyl groups are used, the polymers will degrade slower. Also, increasing molecular weight will cause a decrease in the degradation rate in some cases. Degradation rates of the polymers may be controlled by adjusting the ratio of cationic polymer to linker or by changing the various degradable linker molecules.
- Acrylate linkers are much cheaper than disulfide-containing linkers, because synthesis of the disulfide-containing linkers is more difficult. Acrylate linkers can be hydro lysable in any water solution. Therefore a polymer containing acrylate linkers can be degraded in various environments as long as it contains water. Thus, polymers containing acrylate linkers have broad applications compared to disulfide-linker-containing polymers, hi addition, the degradation rate of polymers with disulfide-linkers are usually the same, but the degradation rate of polymers synthesized with acrylate linkers can vary depending on the different acrylate linkers used.
- the transfection reagent can be mixed with a matrix, such as proteins, peptides, polysaccharides, or other polymers.
- the protein can be gelatin, collagen, bovine serum albumin or any other protein that can be used in affixing proteins to a surface.
- the polymers can be hydrogels, copolymers, non-degradable or biodegradable polymers and biocompatible materials.
- the polysaccharide can be any compound that can form a membrane and coat the delivery reagent, such as chitosan.
- the transfection agent may comprise both a degradable cationic polymer and a non-degradable cationic polymer.
- the ratio of the non-degradable cationic polymer to the degradable cationic polymer is preferably from 1:0.5 to 1:20 (non-degradable : degradable) by weight, and more preferably from 1 :2 to 1 : 10 by weight.
- a gelatin-transfection reagent mixture comprising transfection reagent (e.g., lipid, polymer, lipid-polymer or membrane destabilizing peptide) and gelatin that is present in an appropriate solvent, such as water or double deionized water, may be affixed to the transfection device.
- transfection reagent e.g., lipid, polymer, lipid-polymer or membrane destabilizing peptide
- an appropriate solvent such as water or double deionized water
- a cell culture reagent e.g., fibronectin, collagen, salts, sugars, protein, or peptides
- the mixture is evenly spread onto a surface, such as a slide or multi-well plate, thus producing a transfection surface bearing the gelatin-transfection reagent mixture, hi alternative embodiments, different transfection reagent-gelatin mixtures may also be spotted in discrete regions on the surface of the transfection device.
- the resulting product is allowed to dry completely under suitable conditions such that the gelatin-transfection reagent mixture is affixed at the site of application of the mixture.
- the resulting product can be dried at specific temperatures or humidity or in a vacuum-dessicator.
- the concentration of transfection reagent present in the mixture depends on the transfection efficiency and cytotoxicity of the reagent. Typically there is a balance between transfection efficiency and cytotoxicity. At concentrations in which a transfection reagent is most efficient, while keeping cytotoxicity at an acceptable level, the concentration of transfection reagent is at the optimal level.
- the concentration of transfection reagent will generally be in the range of about 1.0 ⁇ g/ml to about 1000 ⁇ g/ml. In preferred embodiments, the concentration is from about 10 ⁇ g /ml to about 600 ⁇ g/ml.
- the concentration of gelatin or another matrix depends on the experiment or assay to be performed, but the concentration will generally be in the range of 0.01% to 0.5% (w/v) of the transfection reagent solution.
- the molecules to be introduced into cells are nucleic acids.
- the nucleic acid can be DNA, RNA, DNA/RNA hybrid, peptide nucleic acid (PNA), etc.
- the vector can be of any type, such as a plasmid (e.g., plasmid carrying green fluorescence protein (GFP) gene and/or luciferase (luc) gene) or viral-based vector (e.g. pLXSN).
- the DNA can also be linear fragment with a promoter sequence (such as CMV promoter) at the 5' end of the cDNA to be expressed and a poly A site at the 3' end.
- a promoter sequence such as CMV promoter
- These gene expression elements allow the cDNA of interest to be transiently expressed in mammalian cells.
- the DNA is a single strand oligodeoxynucleotide (ODN), for example antisense ODN, it can be introduced into cells to regulate target gene expression.
- ODN oligodeoxynucleotide
- the nucleic acid may be single stranded (antisense RNA and ribozyme) or double stranded (RNA interference, SiRNA).
- the RNA is modified in order to increase the stability of RNA and improve its function in down regulation of gene expression.
- peptide nucleic acid In peptide nucleic acid (PNA), the nucleic acid backbone is replaced by peptide, which makes the molecule more stable.
- the methods described herein can be used to introduce nucleic acids into cells for various purposes, for example molecular therapy, protein function studies, or molecule mechanism studies. Under appropriate conditions, a nucleic acid solution is added into the transfection device, which has been coated with the transfection reagent, to form a nucleic acid transfection reagent complex.
- the nucleic acids are preferably dissolved in cell culture medium without fetal bovine serum and antibiotics, for example Dulbecco's Modified Eagles Medium (DMEM).
- DMEM Dulbecco's Modified Eagles Medium
- any appropriate cell culture media may be used including, but not limited to, Minimum Essential Eagle, F- 12 Kaighn's Modification medium, or RPMI 1640 medium.
- the transfection reagent is evenly affixed on the slide, the nucleic acid solution can be spotted onto discrete locations on the slide. Alternatively, transfection reagents may be spotted on discreet locations on the slide, and the nucleic acid solution can simply be added to cover the whole surface of the transfection device. If the transfection reagent is affixed on the bottom of multi-well plates, the nucleic acid solution is simply added into different wells by multi-channel pipette, automated device, or other delivery methods which are well known in the art.
- the resulting product (transfection device coated with transfection reagent and desired nucleic acid) is incubated for approximately 5 min. to 60 min., more preferably, from 25-30 minutes at room temperature to form the nucleic acid/transfection reagent complex.
- the DNA solution will be removed to produce a surface bearing the nucleic acid samples in complex with the transfection reagent.
- the nucleic acid solution can be kept on the surface.
- cells in an appropriate medium, such as DMEM, and appropriate density are plated onto the surface.
- the resulting product (a surface bearing biomolecules and plated cells) is maintained under conditions that result in entry of the nucleic acids of interest into the plated cells.
- the cells are mixed with the biomolecule or nucleic acid.
- the cell/biomolecule mixture is then added to the transfection device and incubated at room temperature.
- Suitable cells for use according to the methods described herein include prokaryotes, yeast, or higher eukaryotic cells, including plant and animal cells, especially mammalian cells.
- eukaryotic cells such as mammalian cells (e.g., human, monkey, canine, feline, bovine, or murine cells), bacterial, insect or plant cells, are plated onto the transfection device, which is coated with transfection reagent and nucleic acids of interest, in sufficient density and under appropriate conditions for introduction/entry of the nucleic acids of interest into the eukaryotic cells and either expression of the DNA or interaction of the biomolecule with cellular components.
- the cells may be selected from hematopoietic cells, neuronal cells, pancreatic cells, hepatic cells, chondrocytes, osteocytes, or myocytes. The cells can be fully differentiated cells or progenitor/stem cells.
- eukaryotic cells are grown in Dulbecco's Modified Eagles Medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS) with L-glutamine and penicillin/streptomycin (pen/strep).
- DMEM Dulbecco's Modified Eagles Medium
- FBS heat-inactivated fetal bovine serum
- pen/strep penicillin/streptomycin
- the cells are incubated under optimal conditions for the cell type (e.g. 37°C, 5-10% CO 2 ).
- the culture time is dependent on the purpose of experiment. Typically, the cells are incubated for 24 to 48 hours for cells to express the target gene in the case of gene transfection experiments. In the analysis of intracellular trafficking of biomolecules in cells, minutes to several hours of incubation may be required and the cells can be observed at defined time points.
- the target gene expression level can be detected by reporter genes, such as green fluorescent protein (GFP) gene, luciferase gene, or ⁇ -galactosidase gene expression.
- GFP green fluorescent protein
- the signal of GFP can be directly observed under a microscope, the activity of luciferase can be detected by a luminometer, and the blue product catalyzed by ⁇ -galactosidase can be observed under a microscope or determined by a microplate reader.
- GFP green fluorescent protein
- the nucleic acid and its product, or other biomolecules delivered according to methods described herein and the target modulated by these biomolecules can be determined by various methods, such as detecting immunofluorescence or enzyme immunocytochemistry, autoradiography, or in situ hybridization. If immunofluorescence is used to detect expression of an encoded protein, a fluorescently labeled antibody that binds the target protein is used (e.g., added to the slide under conditions suitable for binding of the antibody to the protein). Cells containing the protein are then identified by detecting a fluorescent signal. If the delivered molecules can modulate gene expression, the target gene expression level can also be determined by methods such as autoradiography, in situ hybridization, and in situ PCR. However, the identification method depends on the properties of the delivered biomolecules, their expression product, the target modulated by it, and/or the final product resulting from delivery of the biomolecules.
- PEI-600 in 25 ml of methylene chloride were added by using pipette or syringe. 2.09 g of
- PDODA was quickly added to the above PEI-600 solution with stirring.
- the reaction mixture was stirred for 4 hours at room temperature (20° C). Then, the reaction mixture was neutralized by adding 50 ml of 2M HCl. The white precipitate was centrifuged, washed with methylene chloride, and dried at room temperature under reduced pressure.
- L-PEI Linear polyethyleneimine
- lipid based polymers were used for transfecting plasmid DNA into mammalian cells in vitro to evaluate the transfection efficiency.
- L-PEI based polymer jet PEI (Qbiogene) transfection reagent was used for L-PEI based polymer.
- Lipofectamine2000 (Invitrogen) and N-[l-(2,3-dioleoyloxy)propyl]-N,N,N- trimethylammonium salts (DOTAP; Sigma-Aldrich) were employed as lipid based polymers.
- Degradable cationic polymer and DOTAP were dissolved in methanol, and jet PEI and Lipofectamine2000 were diluted by deionized water.
- Flat bottom 96-well cell culture plates (bottom surface: 0.32 cm 2 per each well; BD Biosciences) were treated with these polymer solutions.
- the actual amounts affixed on the bottom were as follows: (a) Degradable cationic polymer; 3 ⁇ g per well, thus 9.4 ⁇ g/cm 2 , (b) jet PEI; 1 ⁇ l per well, (c) Lipofectamine2000; 0.375 ⁇ g per well, (d) DOTAP; 2 and 4 pmole per well. These plates were dried at room temperature under reduced pressure and sealed in a vacuum pack until use.
- Transfection with Transfectable Cell Culture Device for 293 Cells 25 or 50 ng of pEGFP-Nl plasmid (purchased from Clontech) in 25 ⁇ l of opti- MEM I (hivitrogen) was added in each well and kept at room temperature for 25 minutes. Then, 5 X 10 4 of 293 cells in 100 ⁇ l of Dulbecco's modified Eagle Medium (DMEM) (Invitrogen) with 10% calf serum ( ⁇ nvitrogen) were added and incubated at 37°C in 7.5% of CO 2 . After 24 to 36 hrs. incubation, transfection efficiency was estimated by observing EGFP fluorescence by using epifluorescent microscope (1X70, Olympus).
- DMEM Dulbecco's modified Eagle Medium
- degradable cationic polymer Various amounts of degradable cationic polymer were affixed on the cell culture devices, and transfection efficiency was evaluated.
- 96-well cell culture plates were coated with degradable cationic polymer by the same protocol as shown in Example 2. The actual amount of polymer was as follows: 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 10 and 20 ⁇ g per well. Then, transfection was carried out as described in Example 3 and transfected cells were incubated at 37 0 C in 7.5% of CO 2 . Amount of plasmid DNA added before seeding cells was 0.13, 0.25, 0.50 or 1.0 ⁇ g per well. After 40 hours incubation, percentage of fluorescing cells and cell condition were estimated by epifluorescent microscopy.
- Figure 2 shows percentages of EGFP-positive cells after transfection. High transfection efficiencies were allocated between 2.5 to 5.0 ⁇ g per well (thus, 7.8 to 16 ⁇ g/cm 2 ) of degradable cationic polymer with 0.25 and 0.5 ⁇ g per well (thus, 0.78 to 1.6 ⁇ g/cm 2 ) of plasmid DNA.
- Cell condition in these experiments is shown in Figure 3.
- Cells transfected in the plates with L-PEI and lipid based polymers had rounded shape and had aggregated. The morphology was due to cytotoxicity.
- Cell condition was acceptable when the amount of degradable cationic polymer affixed on the bottom of the plate was from 2.5 to 5.0 ⁇ g per well. Also, all the plasmid DNA conditions that we tested gave us good cell condition with degradable cationic polymer if the amount was from 2.5 to 5.0 ⁇ g per well.
- the coating material is a kind of protein, like collagen or fibronectin.
- these cell culture devices require refrigerated storage which is a disadvantage, especially if they are bulky. For this reason, stability at room temperature is an important feature.
- the cell culture/transfection devices of this invention were tested to study their stability after long-term storage.
- the cell transfection devices were prepared as described in Example 2, and vacuum-sealed in Mylar Bags (Dupont Corp.), which is a film with an oxygen barrier material and aluminum foil with or without oxygen and carbon dioxide absorbers. Storage was at 25°C.
- transfection efficiency with plasmid DNA carrying luciferase gene was tested periodically.
- the procedure for transfectable cell culture devices was as described in Example 3 except the plasmid DNA was different.
- Luciferase activity of cells were determined by using a Dynex MLX Microtiter ® plate luminometer and Luciferase Assay System (Promega Corp. Madison, WI USA) to determine transfection efficiency.
- Figures 4, 5 and 6 show change of transfection efficiencies after storage at 25° C with O 2 and/or CO 2 absorbing materials in Mylar Bags. There was no obvious decrease of transfection efficiency after 5 month storage. Moreover, even when cell culture devices were kept at 25 ° C in Mylar Bags without O 2 and/or CO 2 absorbing materials, transfection efficiency was stable after 5 month and still quite high (Figure 7).
- the cell culture devices of this invention are quite stable at room temperature. The device can be stored without special storage conditions.
- Non-degradable polymer was prepared as follows: Approximately 5 g of polyethlenimine (Aldrich, product number: 408727) was dissolved in 50 ml of dichloromethane, then 100 ml of 2.0M hydrogen chloride in diethyl ether (Aldrich, product number: 455180) was added and mixed well to form polymer hydrochloride. Then, the polymer hydrochloride was collected by centrifuge, and rinsed with 150 ml of diethyl ether. This rinse with diethyl ether was carried out twice. The resultant precipitation after the rinse was dried under vacuum condition at room temperature for 3 hours. Then, the dried powder was stored at 4 0 C with desiccant until use.
- Example 8 Preparation of 96-well Transfectable Cell Culture Device with Degradable Cationic
- Degradable cationic polymer was prepared as indicated in Example 1.
- Non- degradable cationic polymer was obtained as described in Example 7. Both polymers were dissolved in methanol and mixed together to make a coating solution. The final concentration of each polymer was: Degradable cationic polymer; 40 ⁇ g/ml, and Non- degradable cationic polymer; 10 ⁇ g/ml. Then, flat bottom 96-well cell culture plates (bottom surface: 0.32 cm 2 per each well; BD Biosciences) were treated with the coating solution. Actually, 25 ⁇ l of the coating solution was dispensed in each well, and dried under vacuum condition to remove methanol.
- Degradable cationic polymer was prepared as indicated in Example 1.
- Non- degradable cationic polymer was obtained as described in Example 7. Both polymers were dissolved in methanol and mixed together to make a coating solution. The final concentration of each polymer was: Degradable cationic polymer; 80 ⁇ g/ml, and Non- degradable cationic polymer; 10 ⁇ g/ml. Then, flat bottom 12-well cell culture plates (bottom surface: 3.8 cm 2 per each well; BD Biosciences) were treated with these polymer solutions. 100 ⁇ l of the coating solution was dispensed in each well, and dried under vacuum condition to remove methanol.
- Example 10 Preparation of 6-well Transfectable Cell Culture Device with Degradable Cationic Polymer and Non-degradable Cationic Polymer
- Degradable cationic polymer was prepared as indicated in Example 1.
- Non- degradable cationic polymer was obtained as described in Example 7. Both polymers were dissolved in methanol and mixed together to make a coating solution. The final concentration of each polymer was: Degradable cationic polymer; 80 ⁇ g/ml, and Non- degradable cationic polymer; 10 ⁇ g/ml.
- flat bottom 6-well cell culture plates bottom surface: 9.6 cm 2 per each well; BD Biosciences
- Mammalian cells were incubated in 10-cm cell culture dishes, rinsed with phosphate-buffered saline, and treated with trypsin solution. Then, the trypsinized cells were diluted in appropriate cell culture medium with serum to prepare a cell suspension.
- the cell density used in this example is shown in Table 4.
- pEGFP-Nl plasmid was diluted in opti-MEM, and the final concentration was adjusted to 10 ⁇ g/ml. Then, 25 ⁇ l of the plasmid solution was added in each well of the 96- well transferable cell culture device prepared as indicated in Example 8, and kept at room temperature for 25 minutes.
- Table 4 indicates the percentage of the cells with EGFP fluorescence in various mammalian cell lines.
- the 96-well transfectable cell culture device in this invention transfected various mammalian cell lines with high efficiency.
- Example 12 Transfection with 12-well Transfectable Cell Culture Devices Prepared with Degradable and Non-degradable Cationic Polymers
- Mammalian cells were incubated in 10-cm cell culture dishes, rinsed with phosphate-buffered saline, and treated with trypsin solution. Then, the trypsinized cells were diluted in appropriate cell culture medium with serum to prepare cell suspension.
- the cell density used in this example is shown in Table 4.
- pEGFP-Nl plasmid was diluted in opti-MEM, and the final concentration was adjusted to 5 ⁇ g/ml. Then, 200 ⁇ l of the plasmid solution was added in each well of the 12- well transfectable cell culture device prepared as indicated in Example 9, and kept at room temperature for 25 minutes.
- Table 4 indicates the percentage of the cells with EGFP fluorescence in various mammalian cell lines.
- the 12-well transfectable cell culture device in this invention transfected various mammalian cell lines with high efficiency.
- Example 13
- Mammalian cells were incubated in 10-cm cell culture dishes, rinsed with phosphate-buffered saline, and treated with trypsin solution. Then, the trypsinized cells were diluted in appropriate cell culture medium with serum to prepare cell suspension.
- the cell density used in this example is shown in Table 4.
- pEGFP-Nl plasmid was diluted in opti-MEM, and the final concentration was adjusted to 5 ⁇ g/ml. Then, 400 ⁇ l of the plasmid solution was added in each well of the 6- well transfectable cell culture device prepared as indicated in Example 10, and kept at room temperature for 25 minutes. Then, 2 ml of the cell suspension was added in the well, and incubated at 37°C in 7.5% of CO 2 . After 36 to 48-hour incubation, transfection efficiency was estimated by observing EGFP fluorescence by using epifluorescent microscope (1X70, Olympus).
- Table 4 indicates the percentage of the cells with EGFP fluorescence in various mammalian cell lines.
- the 6-well transfectable cell culture device in this invention transfected various mammalian cell lines with high efficiency.
- HeLa 70 80 70 1.0-2.0x10 s 1.0x10 s 0.5x10 s
- CV- 1 20-30 30 20-30 1.0x10 s 1.5x10 5 1.5x10 s
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005316501A AU2005316501B2 (en) | 2004-12-17 | 2005-12-14 | Immobilized degradable cationic polymer for transfecting eukaryotic cells |
EP05854197A EP1836293A2 (en) | 2004-12-17 | 2005-12-14 | Immobilized degradable cationic polymer for transfecting eukaryotic cells |
CA002590820A CA2590820A1 (en) | 2004-12-17 | 2005-12-14 | Immobilized degradable cationic polymer for transfecting eukaryotic cells |
KR1020137000063A KR20130010036A (en) | 2004-12-17 | 2005-12-14 | Immobilized degradable cationic polymer for transfecting eukaryotic cells |
JP2007546895A JP4739352B2 (en) | 2004-12-17 | 2005-12-14 | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63734404P | 2004-12-17 | 2004-12-17 | |
US60/637,344 | 2004-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006066001A2 true WO2006066001A2 (en) | 2006-06-22 |
WO2006066001A3 WO2006066001A3 (en) | 2006-09-08 |
Family
ID=36353906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/045429 WO2006066001A2 (en) | 2004-12-17 | 2005-12-14 | Immobilized degradable cationic polymer for transfecting eukaryotic cells |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1836293A2 (en) |
JP (1) | JP4739352B2 (en) |
KR (2) | KR101263173B1 (en) |
CN (1) | CN101124316A (en) |
AU (1) | AU2005316501B2 (en) |
CA (1) | CA2590820A1 (en) |
WO (1) | WO2006066001A2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010524506A (en) * | 2007-04-27 | 2010-07-22 | ダウ グローバル テクノロジーズ インコーポレイティド | Methods for rapidly screening microbial hosts to identify specific strains with improved yield and / or quality of heterologous protein expression |
JP2010533493A (en) * | 2007-07-13 | 2010-10-28 | ハンディーラブ インコーポレイテッド | Polynucleotide capture material and method of use thereof |
US8258235B2 (en) | 2004-10-04 | 2012-09-04 | Nitto Denko Corporation | Biodegradable cationic polymers |
WO2014207231A1 (en) * | 2013-06-28 | 2014-12-31 | Ethris Gmbh | Compositions for introducing rna into cells |
US9080207B2 (en) | 2006-03-24 | 2015-07-14 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US9480983B2 (en) | 2011-09-30 | 2016-11-01 | Becton, Dickinson And Company | Unitized reagent strip |
US9618139B2 (en) | 2007-07-13 | 2017-04-11 | Handylab, Inc. | Integrated heater and magnetic separator |
US9670528B2 (en) | 2003-07-31 | 2017-06-06 | Handylab, Inc. | Processing particle-containing samples |
US9677121B2 (en) | 2001-03-28 | 2017-06-13 | Handylab, Inc. | Systems and methods for thermal actuation of microfluidic devices |
US9765389B2 (en) | 2011-04-15 | 2017-09-19 | Becton, Dickinson And Company | Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection |
US9802199B2 (en) | 2006-03-24 | 2017-10-31 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US9815057B2 (en) | 2006-11-14 | 2017-11-14 | Handylab, Inc. | Microfluidic cartridge and method of making same |
US10041102B2 (en) | 2002-10-08 | 2018-08-07 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
US10065185B2 (en) | 2007-07-13 | 2018-09-04 | Handylab, Inc. | Microfluidic cartridge |
US10071376B2 (en) | 2007-07-13 | 2018-09-11 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
USD831843S1 (en) | 2011-09-30 | 2018-10-23 | Becton, Dickinson And Company | Single piece reagent holder |
US10179910B2 (en) | 2007-07-13 | 2019-01-15 | Handylab, Inc. | Rack for sample tubes and reagent holders |
US10234474B2 (en) | 2007-07-13 | 2019-03-19 | Handylab, Inc. | Automated pipetting apparatus having a combined liquid pump and pipette head system |
US10364456B2 (en) | 2004-05-03 | 2019-07-30 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
EP3542825A1 (en) * | 2014-11-10 | 2019-09-25 | Ethris GmbH | Induction of osteogenesis by delivering bmp encoding rna |
US10571935B2 (en) | 2001-03-28 | 2020-02-25 | Handylab, Inc. | Methods and systems for control of general purpose microfluidic devices |
US10689640B2 (en) | 2007-04-27 | 2020-06-23 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US10799862B2 (en) | 2006-03-24 | 2020-10-13 | Handylab, Inc. | Integrated system for processing microfluidic samples, and method of using same |
US10822644B2 (en) | 2012-02-03 | 2020-11-03 | Becton, Dickinson And Company | External files for distribution of molecular diagnostic tests and determination of compatibility between tests |
US10900066B2 (en) | 2006-03-24 | 2021-01-26 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
CN114904003A (en) * | 2021-02-09 | 2022-08-16 | 中山大学 | Application of ionizable cationic lipid analogue material as nucleic acid drug delivery carrier or transfection reagent |
US11453906B2 (en) | 2011-11-04 | 2022-09-27 | Handylab, Inc. | Multiplexed diagnostic detection apparatus and methods |
US11806718B2 (en) | 2006-03-24 | 2023-11-07 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6692700B2 (en) | 2001-02-14 | 2004-02-17 | Handylab, Inc. | Heat-reduction methods and systems related to microfluidic devices |
US6852287B2 (en) | 2001-09-12 | 2005-02-08 | Handylab, Inc. | Microfluidic devices having a reduced number of input and output connections |
US7010391B2 (en) | 2001-03-28 | 2006-03-07 | Handylab, Inc. | Methods and systems for control of microfluidic devices |
EP2412816B1 (en) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Process for improved protein expression by strain engineering |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
US8133671B2 (en) | 2007-07-13 | 2012-03-13 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
USD787087S1 (en) | 2008-07-14 | 2017-05-16 | Handylab, Inc. | Housing |
CN102827756B (en) * | 2012-06-25 | 2014-04-09 | 华南农业大学 | Agrobacterium local invasion method applied in soybean hypocotyl explant transformation system, and device thereof |
BR112019006671A2 (en) * | 2016-10-05 | 2019-06-25 | Syngenta Participations Ag | improvements in or related to gene silencing |
CN109735573A (en) * | 2019-02-19 | 2019-05-10 | 武汉普诺赛生命科技有限公司 | A kind of transient transfection reagent and its application method |
EP3798250A1 (en) * | 2019-09-25 | 2021-03-31 | University College Dublin | Hyperbranched cationic polymers useful as nucleic acid delivery vectors for transfecting |
CN112195193A (en) * | 2020-09-30 | 2021-01-08 | 上海交通大学 | Application of single-stranded DNA in gene transfection |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
EP1398042A1 (en) * | 2002-09-10 | 2004-03-17 | Lipotek, Inc | Transfection of nucleic acid |
US20040138154A1 (en) * | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
WO2005023312A2 (en) * | 2003-09-03 | 2005-03-17 | Imperial College Innovations Limited | Methods for transfecting cells using dna minor groove binding agents |
US20050176132A1 (en) * | 2004-02-10 | 2005-08-11 | Yasunobu Tanaka | Culture device and method for eukaryotic cell transfection |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020006664A1 (en) * | 1999-09-17 | 2002-01-17 | Sabatini David M. | Arrayed transfection method and uses related thereto |
DE60031997D1 (en) * | 1999-09-17 | 2007-01-04 | Whitehead Biomedical Inst | UMKEHRTRANSFEKTIONSVERFAHREN |
JP2005505231A (en) * | 2000-11-03 | 2005-02-24 | リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Surface transfection and expression methods |
US20030235916A1 (en) * | 2002-06-14 | 2003-12-25 | Monahan Sean D. | Novel methods for the delivery of polynucleotides to cells |
US6878374B2 (en) * | 2003-02-25 | 2005-04-12 | Nitto Denko Corporation | Biodegradable polyacetals |
EP1723240B1 (en) * | 2004-02-18 | 2010-08-11 | Nitto Denko Corporation | Culture device and method for eukaryotic cell transfection |
-
2005
- 2005-12-14 KR KR1020077015797A patent/KR101263173B1/en not_active IP Right Cessation
- 2005-12-14 AU AU2005316501A patent/AU2005316501B2/en not_active Ceased
- 2005-12-14 CA CA002590820A patent/CA2590820A1/en not_active Abandoned
- 2005-12-14 WO PCT/US2005/045429 patent/WO2006066001A2/en active Application Filing
- 2005-12-14 EP EP05854197A patent/EP1836293A2/en not_active Withdrawn
- 2005-12-14 CN CNA2005800434531A patent/CN101124316A/en active Pending
- 2005-12-14 JP JP2007546895A patent/JP4739352B2/en not_active Expired - Fee Related
- 2005-12-14 KR KR1020137000063A patent/KR20130010036A/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
EP1398042A1 (en) * | 2002-09-10 | 2004-03-17 | Lipotek, Inc | Transfection of nucleic acid |
US20040138154A1 (en) * | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
WO2005023312A2 (en) * | 2003-09-03 | 2005-03-17 | Imperial College Innovations Limited | Methods for transfecting cells using dna minor groove binding agents |
US20050176132A1 (en) * | 2004-02-10 | 2005-08-11 | Yasunobu Tanaka | Culture device and method for eukaryotic cell transfection |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10619191B2 (en) | 2001-03-28 | 2020-04-14 | Handylab, Inc. | Systems and methods for thermal actuation of microfluidic devices |
US10351901B2 (en) | 2001-03-28 | 2019-07-16 | Handylab, Inc. | Systems and methods for thermal actuation of microfluidic devices |
US10571935B2 (en) | 2001-03-28 | 2020-02-25 | Handylab, Inc. | Methods and systems for control of general purpose microfluidic devices |
US9677121B2 (en) | 2001-03-28 | 2017-06-13 | Handylab, Inc. | Systems and methods for thermal actuation of microfluidic devices |
US10041102B2 (en) | 2002-10-08 | 2018-08-07 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
US11078523B2 (en) | 2003-07-31 | 2021-08-03 | Handylab, Inc. | Processing particle-containing samples |
US10865437B2 (en) | 2003-07-31 | 2020-12-15 | Handylab, Inc. | Processing particle-containing samples |
US9670528B2 (en) | 2003-07-31 | 2017-06-06 | Handylab, Inc. | Processing particle-containing samples |
US10731201B2 (en) | 2003-07-31 | 2020-08-04 | Handylab, Inc. | Processing particle-containing samples |
US10604788B2 (en) | 2004-05-03 | 2020-03-31 | Handylab, Inc. | System for processing polynucleotide-containing samples |
US10443088B1 (en) | 2004-05-03 | 2019-10-15 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
US10494663B1 (en) | 2004-05-03 | 2019-12-03 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
US10364456B2 (en) | 2004-05-03 | 2019-07-30 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
US11441171B2 (en) | 2004-05-03 | 2022-09-13 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
US8258235B2 (en) | 2004-10-04 | 2012-09-04 | Nitto Denko Corporation | Biodegradable cationic polymers |
US11085069B2 (en) | 2006-03-24 | 2021-08-10 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US9802199B2 (en) | 2006-03-24 | 2017-10-31 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US11806718B2 (en) | 2006-03-24 | 2023-11-07 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US10857535B2 (en) | 2006-03-24 | 2020-12-08 | Handylab, Inc. | Integrated system for processing microfluidic samples, and method of using same |
US11666903B2 (en) | 2006-03-24 | 2023-06-06 | Handylab, Inc. | Integrated system for processing microfluidic samples, and method of using same |
US10843188B2 (en) | 2006-03-24 | 2020-11-24 | Handylab, Inc. | Integrated system for processing microfluidic samples, and method of using the same |
US10821436B2 (en) | 2006-03-24 | 2020-11-03 | Handylab, Inc. | Integrated system for processing microfluidic samples, and method of using the same |
US10821446B1 (en) | 2006-03-24 | 2020-11-03 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US10799862B2 (en) | 2006-03-24 | 2020-10-13 | Handylab, Inc. | Integrated system for processing microfluidic samples, and method of using same |
US10900066B2 (en) | 2006-03-24 | 2021-01-26 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US10913061B2 (en) | 2006-03-24 | 2021-02-09 | Handylab, Inc. | Integrated system for processing microfluidic samples, and method of using the same |
US10695764B2 (en) | 2006-03-24 | 2020-06-30 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US11142785B2 (en) | 2006-03-24 | 2021-10-12 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US11141734B2 (en) | 2006-03-24 | 2021-10-12 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US9080207B2 (en) | 2006-03-24 | 2015-07-14 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US10710069B2 (en) | 2006-11-14 | 2020-07-14 | Handylab, Inc. | Microfluidic valve and method of making same |
US9815057B2 (en) | 2006-11-14 | 2017-11-14 | Handylab, Inc. | Microfluidic cartridge and method of making same |
US10689640B2 (en) | 2007-04-27 | 2020-06-23 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
JP2010524506A (en) * | 2007-04-27 | 2010-07-22 | ダウ グローバル テクノロジーズ インコーポレイティド | Methods for rapidly screening microbial hosts to identify specific strains with improved yield and / or quality of heterologous protein expression |
US10100302B2 (en) | 2007-07-13 | 2018-10-16 | Handylab, Inc. | Polynucleotide capture materials, and methods of using same |
US11266987B2 (en) | 2007-07-13 | 2022-03-08 | Handylab, Inc. | Microfluidic cartridge |
US10632466B1 (en) | 2007-07-13 | 2020-04-28 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US10625262B2 (en) | 2007-07-13 | 2020-04-21 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US10590410B2 (en) | 2007-07-13 | 2020-03-17 | Handylab, Inc. | Polynucleotide capture materials, and methods of using same |
JP2010533493A (en) * | 2007-07-13 | 2010-10-28 | ハンディーラブ インコーポレイテッド | Polynucleotide capture material and method of use thereof |
US10717085B2 (en) | 2007-07-13 | 2020-07-21 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
JP2013255517A (en) * | 2007-07-13 | 2013-12-26 | Handylab Inc | Polynucleotide capture material and method for using the same |
US11549959B2 (en) | 2007-07-13 | 2023-01-10 | Handylab, Inc. | Automated pipetting apparatus having a combined liquid pump and pipette head system |
US10234474B2 (en) | 2007-07-13 | 2019-03-19 | Handylab, Inc. | Automated pipetting apparatus having a combined liquid pump and pipette head system |
US11466263B2 (en) | 2007-07-13 | 2022-10-11 | Handylab, Inc. | Diagnostic apparatus to extract nucleic acids including a magnetic assembly and a heater assembly |
US10179910B2 (en) | 2007-07-13 | 2019-01-15 | Handylab, Inc. | Rack for sample tubes and reagent holders |
US10139012B2 (en) | 2007-07-13 | 2018-11-27 | Handylab, Inc. | Integrated heater and magnetic separator |
US10625261B2 (en) | 2007-07-13 | 2020-04-21 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US11254927B2 (en) | 2007-07-13 | 2022-02-22 | Handylab, Inc. | Polynucleotide capture materials, and systems using same |
US10844368B2 (en) | 2007-07-13 | 2020-11-24 | Handylab, Inc. | Diagnostic apparatus to extract nucleic acids including a magnetic assembly and a heater assembly |
JP2015133995A (en) * | 2007-07-13 | 2015-07-27 | ハンディーラブ インコーポレイテッド | Polynucleotide capture materials, and methods of using the same |
JP2017060501A (en) * | 2007-07-13 | 2017-03-30 | ハンディーラブ インコーポレイテッド | Polynucleotide capture materials, and methods of using the same |
US10071376B2 (en) | 2007-07-13 | 2018-09-11 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US10875022B2 (en) | 2007-07-13 | 2020-12-29 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US10065185B2 (en) | 2007-07-13 | 2018-09-04 | Handylab, Inc. | Microfluidic cartridge |
US9618139B2 (en) | 2007-07-13 | 2017-04-11 | Handylab, Inc. | Integrated heater and magnetic separator |
US11060082B2 (en) | 2007-07-13 | 2021-07-13 | Handy Lab, Inc. | Polynucleotide capture materials, and systems using same |
US11788127B2 (en) | 2011-04-15 | 2023-10-17 | Becton, Dickinson And Company | Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection |
US10781482B2 (en) | 2011-04-15 | 2020-09-22 | Becton, Dickinson And Company | Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection |
US9765389B2 (en) | 2011-04-15 | 2017-09-19 | Becton, Dickinson And Company | Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection |
USD905269S1 (en) | 2011-09-30 | 2020-12-15 | Becton, Dickinson And Company | Single piece reagent holder |
US9480983B2 (en) | 2011-09-30 | 2016-11-01 | Becton, Dickinson And Company | Unitized reagent strip |
US10076754B2 (en) | 2011-09-30 | 2018-09-18 | Becton, Dickinson And Company | Unitized reagent strip |
USD831843S1 (en) | 2011-09-30 | 2018-10-23 | Becton, Dickinson And Company | Single piece reagent holder |
US11453906B2 (en) | 2011-11-04 | 2022-09-27 | Handylab, Inc. | Multiplexed diagnostic detection apparatus and methods |
US10822644B2 (en) | 2012-02-03 | 2020-11-03 | Becton, Dickinson And Company | External files for distribution of molecular diagnostic tests and determination of compatibility between tests |
WO2014207231A1 (en) * | 2013-06-28 | 2014-12-31 | Ethris Gmbh | Compositions for introducing rna into cells |
EA036400B1 (en) * | 2013-06-28 | 2020-11-06 | Этрис Гмбх | Compositions for introducing rna into cells |
AU2014300980B2 (en) * | 2013-06-28 | 2020-03-05 | Ethris Gmbh | Compositions for introducing RNA into cells |
EP3542825A1 (en) * | 2014-11-10 | 2019-09-25 | Ethris GmbH | Induction of osteogenesis by delivering bmp encoding rna |
CN114904003A (en) * | 2021-02-09 | 2022-08-16 | 中山大学 | Application of ionizable cationic lipid analogue material as nucleic acid drug delivery carrier or transfection reagent |
CN114904003B (en) * | 2021-02-09 | 2023-09-29 | 广州立得生物医药科技有限公司 | Use of ionizable cationic lipid analog materials as nucleic acid drug delivery vehicles or transfection reagents |
Also Published As
Publication number | Publication date |
---|---|
CN101124316A (en) | 2008-02-13 |
EP1836293A2 (en) | 2007-09-26 |
KR101263173B1 (en) | 2013-05-13 |
AU2005316501B2 (en) | 2010-10-21 |
AU2005316501A1 (en) | 2006-06-22 |
JP4739352B2 (en) | 2011-08-03 |
KR20130010036A (en) | 2013-01-24 |
WO2006066001A3 (en) | 2006-09-08 |
CA2590820A1 (en) | 2006-06-22 |
KR20070101859A (en) | 2007-10-17 |
JP2008523810A (en) | 2008-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005316501B2 (en) | Immobilized degradable cationic polymer for transfecting eukaryotic cells | |
US20070269891A9 (en) | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells | |
US8192989B2 (en) | Solid surface for biomolecule delivery and high-throughput assay | |
AU2005294699B2 (en) | Biodegradable cationic polymers | |
US20080312174A1 (en) | Water soluble crosslinked polymers | |
JP2021531780A (en) | Bio ink for 3D printing | |
US7125709B2 (en) | Culture device and method for eukaryotic cell transfection | |
EP1723240B1 (en) | Culture device and method for eukaryotic cell transfection | |
Schlaeger et al. | Transient transfection in mammalian cells: a basic study for an efficient and cost-effective scale up process | |
AU2012200435A1 (en) | "Biodegradable cationic polymers" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005316501 Country of ref document: AU Ref document number: 2590820 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007546895 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580043453.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
ENP | Entry into the national phase in: |
Ref document number: 2005316501 Country of ref document: AU Date of ref document: 20051214 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005316501 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077015797 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005854197 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005854197 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020137000063 Country of ref document: KR |